Downregulation of RhoB GTPase confers resistance to cisplatin in human laryngeal carcinoma cells

Cancer Letters

Volumn 295, Issue 2, 2010, Pages 182-190

  Čimbora Zovko, Tamara ^a   Fritz, Gerhard ^b   Mikac, Nevenka ^a   Osmak, Maja ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cisplatin; Drug resistance; Rho GTPases; RhoB

Indexed keywords

CISPLATIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; GENETIC TRANSFECTION; HEP 2 CELL; HUMAN; HUMAN CELL; LARYNX CARCINOMA; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LARYNGEAL NEOPLASMS; RHOB GTP-BINDING PROTEIN;

EID: 77953979830     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.025     Document Type: Article

References (47)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
2. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000, 59:9-17.
3. Ambriović-Ristov A., Osmak M. Integrin-mediated drug resistance. Curr. Signal. Transduct. Ther. 2006, 1:227-237.
4. Brozovic A., Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2007, 251:1-16.
5. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007, 63:12-31.
6. Schwartz M.A., Shattil S.J. Signaling networks linking integrins and rho family GTPases. Trends Biochem. Sci. 2000, 25:388-391.
7. 5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int. J. Cancer 2008, 123:357-364.
8. Vega F.M., Ridley A.J. Rho GTPases in cancer cell biology. FEBS Lett. 2008, 582:2093-2101.
9. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
10. Huang M., Prendergast G.C. RhoB in cancer suppression. Histol. Histopathol. 2006, 21:213-218.
11. Jiang K., Delarue F.L., Sebti S.M. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004, 23:1136-1145.
12. Jiang K., Sun J., Cheng J., Djeu J.Y., Wei S., Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 2004, 24:5565-5576.
13. Zhang B., Zhang Y., Shacter E. Caspase 3-mediated inactivation of rac GTPases promotes drug-induced apoptosis in human lymphoma cells. Mol. Cell. Biol. 2003, 23:5716-5725.
14. Fellenberg J., Dechant M.J., Ewerbeck V., Mau H. Identification of drug-regulated genes in osteosarcoma cells. Int. J. Cancer 2003, 105:636-643.
15. Shen D.W., Su A., Liang X.J., Pai-Panandiker A., Gottesman M.M. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 2004, 91:270-276.
16. Fritz G., Kaina B., Aktories K. The ras-related small GTP-binding protein RhoB is immediate-early enducible by DNA damaging treatments. J. Biol. Chem. 1995, 270:25172-25177.
17. Fritz G., Kaina B. Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem. Biophys. Res. Commun. 2000, 268:784-789.
18. Zhang B., Zhang Y., Dagher M.C., Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005, 65:6054-6062.
19. Čimbora-Zovko T., Ambriović-Ristov A., Lončarek J., Osmak M. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between β-catenin/plakoglobin ratio and cisplatin resistance. Eur. J. Pharmacol. 2007, 558:27-36.
20. 3 and coxsackie adenovirus receptor. Int. J. Cancer 2004, 110:660-667.
21. Osmak M., Beketić-Orešković L., Matulić M., Sorić J. Resistance of human larynx carcinoma cells to cisplatin, gamma-irradiation and methotrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes. Mutat. Res. 1993, 303:113-120.
22. Osmak M., Eljuga D. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res. Exp. Med. (Berl). 1993, 193:389-396.
23. Kern M.A., Helmbach H., Artuc M., Karmann D., Jurgovsky K., Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide - modulation of proto-oncogene expression. Anticancer Res. 1997, 17:4359-4370.
24. Fritz G., Brachetti C., Bahlmann F., Schmidt M., Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer 2002, 87:635-644.
25. Chen Z., Sun J., Pradines A., Favre G., Adnane J., Sebti S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 2000, 275:17974-17978.
26. Safaei R., Katano K., Larson B.J., Samimi G., Holzer A.K., Naerdemann W., Tomioka M., Goodman M., Howell S.B. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin. Cancer Res. 2005, 11:756-767.
27. Jahner D., Hunter T. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol. Cell. Biol. 1991, 11:3682-3690.
28. Fritz G., Gnad R., Kaina B. Cell and tissue-type specific expression of Ras-related GTPase RhoB. Anticancer Res. 1999, 19:1681-1688.
29. Trapp T., Olah L., Holker I., Besselmann M., Tiesler C., Maeda K., Hossmann K.A. GTPase RhoB: an early predictor of neuronal death after transient focal ischemia in mice. Mol. Cell. Neurosci. 2001, 17:883-894.
30. Gamelin E., Allain P., Maillart P., Turcant A., Delva R., Lortholary A., Larra F. Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother. Pharmacol. 1995, 37:97-102.
31. Zalcman G., Closson V., Linarescruz G., Lerebours F., Honore N., Tavitian A., Olofsson B. Regulation of Ras-related RhoB protein expression during the cell cycle. Oncogene 1995, 10:1935-1945.
32. Fritz G., Kaina B. Ras-related GTPase RhoB represses NF-κB signaling. J. Biol. Chem. 2001, 276:3115-3122.
33. Michaelson D., Silletti J., Murphy G., D'Eustachio P., Rush M., Philips M.R. Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J. Cell Biol. 2001, 152:111-126.
34. Adamson P., Marshall C.J., Hall A., Tilbrook P.A. Post-translational modifications of p21rho proteins. J. Biol. Chem. 1992, 267:20033-20038.
35. Mazieres J., Tillement V., Allal C., Clanet C., Bobin L., Chen Z., Sebti S.M., Favre G., Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp. Cell Res. 2005, 304:354-364.
36. Milia J., Teyssier F., Dalenc F., Ader I., Delmas C., Pradines A., Lajoie-Mazenc I., Baron R., Bonnet J., Cohen-Jonathan E., Favre G., Toulas C. Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ. 2005, 12:492-501.
37. Adnane J., Muro-Cacho C., Mathews L., Sebti S.M., Munoz-Antonia T. Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients. Clin. Cancer Res. 2002, 8:2225-2232.
38. Ader I., Toulas C., Dalenc F., Delmas C., Bonnet J., Cohen-Jonathan E., Favre G. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 2002, 21:5998-6006.
39. Gebhard P.M., Soder S., Bau B., Aigner T. Down-regulation of the GTPase RhoB might be involved in the pre-apoptotic phenotype of osteoarthritic chondrocytes. Front. Biosci. 2004, 9:827-833.
40. de Cremoux P., Gauville C., Closson V., Linares G., Calvo F., Tavitian A., Olofsson B. EGF modulation of the ras-related rhoB gene expression in human breast-cancer cell lines. Int. J. Cancer 1994, 59:408-415.
41. Skuli N., Monferran S., Delmas C., Lajoie-Mazenc I., Favre G., Toulas C., Cohen-Jonathan-Moyal E. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1α stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res. 2006, 66:482-489.
42. Canguilhem B., Pradines A., Baudouin C., Boby C., Lajoie-Mazenc I., Charveron M., Favre G. RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J. Biol. Chem. 2005, 280:43257-43263.
43. Ader I., Delmas C., Bonnet J., Rochaix P., Favre G., Toulas C., Cohen-Jonathan-Moyal E. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 2003, 22:8861-8869.
44. Liu A., Cerniglia G.J., Bernhard E.J., Prendergast G.C. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. USA 2001, 98:6192-6197.
45. Chen Y.X., Li Z.B., Diao F., Cao D.M., Fu C.C., Lu J. Up-regulation of RhoB by glucocorticoids and its effects on the cell proliferation and NF-κB transcriptional activity. J. Steroid Biochem. Mol. Biol. 2006, 101:179-187.
46. Rodriguez P.L., Sahay S., Olabisi O.O., Whitehead I.P. ROCK I-mediated activation of NF-κB by RhoB. Cell. Signal. 2007, 19:2361-2369.
47. Couderc B., Pradines A., Rafii A., Golzio M., Deviers A., Allal C., Berg D., Penary M., Teissie J., Favre G. In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther. 2008, 15:456-464.